Stock Up 300% In Six Weeks -- But There's More... Right?
Ophir Gottlieb | Sep 05, 2012 02:03AM ET
Sarepta Therapeutics Inc., (SRPT) formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid-based (RNA) therapeutics for the treatment of both rare and infectious diseases.
This is a vol and stock note on a bio-tech with some very interesting news. I'll summarize what's the happs below, then we'll move onto the options and vol. I'll be taking a chunk of this content from a Seeking Alpha article, cited below:
Sarepta Therapeutics (SRPT), formerly known as AVI BioPharma, is closing in on a significant medical breakthrough for the largest segment of Duchenne Muscular Dystrophy sufferers. Duchenne Muscular Dystrophy is an affliction that results in muscle degeneration and certain early death. It affects mostly boys with most sufferers wheelchair dependent by age 12 and a life expectancy of 25 years. There is no known cure for Duchenne Muscular Dystrophy.
Sarepta's stock has been on a tear the last five weeks going from around $4 per share on July 23rd and closing at $15.82 August 31. The catalyst for this move was Sarepta's release of 36-week data of their current phase IIb extension study that, according to Sarepta's CEO Chris Garabedian, showed "statistically significant clinical benefit" in the 6 minute walk test - which is a "clinical meaningful outcome measure" for Duchenne Muscular Dystrophy.
[...] that the lead investigator for the trial is Dr. Jerry Mendell, who is the director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital in Columbus, OH. Dr. Mendell stated Sarepta's drug had "an unprecedented treatment effect" on participants in its latest trial.
Sarepta plans to release the full 48-week trial results for the above referenced study in October. If the results are positive as expected, Sarepta will go for accelerated FDA approval. --
Source: Seeking Alpha via Yahoo! Finance; Sarepta surges on new muscular dystrophy drug data .
The stock found a bit of a quiet period following the gap up, but has recently risen again. The stock closed at $10.78 on 8-24-2012 and is now nearly 40% higher in about two weeks.
On the vol side we have a bit murkier of a picture since the stock changed symbols recently. Having said that, we can see that the implied is now at an annual high pushing over 140%. But the news is due out in Oct (probably), and the Skew Tab shows us that.
Let's turn to the Skew Tab to examine the line-by-line and month-to-month vols.
We can see high the vol in the Oct options is well above the vol in Sep and Nov. This reflects the likelihood of an event (announcement) in Oct. I do note that the skew is flat to the upside, which is not necessarily what I would have expected given the interim good news. Having said that, with the stock up 400% (or whatever) in the last 6 weeks, the option market may be reflecting lower risk (potential) from the current levels than when this was a single digit stock price.
Get The News You Want
Finally, let's turn to the Options Tab, for completeness.
Across the top we can see the monthly vols are priced to 113.66%, 176.40% and 154.32%, respectively for Sep, Oct and Nov. I do note a few things:
1. Sep is still elevated which reflects the risk that "something" comes out before the expected Oct date. That something may just be more anecdotal results from extremely happy parents (that's been happening apparently).
2. Oct vol will likely rise if no new news slips out. As the event date approaches, the weighted average of vols in Oct will lead to a rise in the overall level. 200%+ vol is not impossible here and may be too low. But, of course, surprise news can change all of that.
3. Nov is quite elevated. While that expiry does include all of the days in Oct, it feels like there is risk of the news coming out after Oct expo (maybe?).
In any case, all options and stock prices aside, I hope this drug is an absolute revelation as it seems to be in early stages. I can honestly say, I am rooting for this company.
Disclosure: This is trade analysis, not a recommendation.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.